Clinical Trial Detail

NCT ID NCT02273375
Title Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors NCIC Clinical Trials Group
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Age Groups: adult

No variant requirements are available.